A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder
ACTIVE_NOT_RECRUITING
Status
Conditions
- Major Depressive Disorder
Interventions
Sponsor
COMPASS Pathways